Syra Health Q3 10-Q: $835,831 Nine-Month Profit, Yet Going-Concern Warning Persists
SYRA has more than doubled off its 52-week low of $0.056 on elevated volume (5.2× avg).
Summary
Syra Health's Q3 10-Q shows nine-month net income of $835,831 on revenue of $7,225,238 and $975,023 of operating cash inflow, but the filing still includes a substantial-doubt going-concern warning given its $8,884,695 accumulated deficit.
Key Events · Earnings and Guidance · SYRA
-
Q3 Profit and 52% Revenue Growth
Third-quarter revenue came in at $2,557,295 versus $1,687,971 a year earlier, and net income was $344,610 versus a $225,902 loss.
-
Nine-Month Swing to Profit
For the nine months, net income reached $835,831 against a $761,763 loss in the prior-year period, on revenue of $7,225,238 (up from $5,491,944).
-
Going-Concern Warning Remains
Management cites substantial doubt about continuing as a going concern, with $2,383,413 of cash, $2,962,208 of working capital and an $8,884,695 accumulated deficit.
-
Operating Cash Flow Turns Positive
Operations provided $975,023 of cash for the nine months versus $158,554 used a year earlier; financing used $206,343 for note repayments.
Analysis · SYRA · Trade & Services
What matters here is the tension: real profitability and positive operating cash flow sit alongside a formal doubt about survival. Q3 revenue of $2,557,295 rose 52% year over year, and net income of $344,610 flipped from a $225,902 loss; for the nine months, the company swung to $835,831 of net income from a $761,763 loss. Gross margin expanded to about 45% from 35% as the mix shifted toward higher-margin population health work, and operations generated $975,023 of cash instead of burning it. Against that, the filing still carries an explicit going-concern paragraph: with $2,383,413 of cash and an $8,884,695 accumulated deficit, management says it may not have enough funds for the next twelve months and may need to raise more capital. That is the detail the press release did not carry. The company also remains heavily dependent on a few customers, with Humana at roughly 35% of revenue.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYRA was trading at $0.93 on OTC in the Trade & Services sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.06 to $1.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.